Use of E-health Based Exercise Intervention After COVID-19

NCT ID: NCT05770505

Last Updated: 2026-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

77 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-17

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Reduced subjective and objective functional capacity performance are reported after COVID-19 in a large proportion of subjects. The aim of this study is to examine the feasibility and effect of using an e-health tool for guidance and tracking of exercise training in a general population of adults previously infected by COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Both hospitalized and non-hospitalized persons who have undergone extensive multi-disciplinary rehabilitation programs report significantly improved physical function after rehabilitation. Exercise training may be the key intervention to improve fitness and subjective complaints such as fatigue, low physical fitness and dyspnea after COVID-19 infection. However, traditional group-based exercise training or self-training programs at fitness centers have been shut down during the pandemic, and home-based interventions are warranted. To overcome the limitations and costs of a fitness center/personal trainer-based intervention study, more knowledge on the effectiveness and efficacy of using an e-Health system to recruit, train and monitor participants after illness are needed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supervised exercise

Group Type EXPERIMENTAL

Exercise training using an e-health tool

Intervention Type BEHAVIORAL

Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Activity Quotient (AQ) equivalents per week Control: No follow-up

Control group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise training using an e-health tool

Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Activity Quotient (AQ) equivalents per week Control: No follow-up

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons who have undergone COVID-19 disease
* People who struggle to be physically active enough as a result of corona disease
* People who experience reduced physical fitness as a result of corona disease

Exclusion Criteria

\-- more than 100 AQ per week (calculated from self-reported activity level)

* uncontrolled hypertension (high blood pressure) (over 200/110).
* symptomatic valve failure, hypertrophic cardiomyopathy, unstable angina, pulmonary
* hypertension, heart failure and/or severe rhythm disturbances
* cancer that makes participation impossible or exercise contraindicated. Considered individually in consultation with the attending physician.
* chronic contagious infectious diseases.
* Participates in other studies that are not compatible with participation in this project
* Post-exertional symptom exacerbation (PESE)/post-exertional malaise (PEM)/post-exertional neuroimmune exhaustion (PENE).
Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oslo

OTHER

Sponsor Role collaborator

Norwegian University of Science and Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dorthe Stensvold Stensvold

Role: PRINCIPAL_INVESTIGATOR

Dorthe Stensvold, Professor, NTNU

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Norwegian University of Science and Technology, Faculty of medicine, Department of circulation and medical imaging,

Trondheim, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

479316

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Physical Activity Post COVID-19
NCT04768257 COMPLETED